Commercial Capsules: Pfizer's Tax Reform M&A Pause; PARP Deals; PD-1 Sales; Antimicrobial Financing
Pfizer's CEO says uncertainty over US tax reform was staying his hand in M&A; following AstraZeneca's MYSTIC miss, Bristol-Myers Squibb and Merck & Co. were duly grilled over their own PD-1/CTLA-4 combination programs; recent deals highlight gathering enthusiasm for combining PARP and PD-1/PD-L1 inhibition. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
You may also be interested in...
Amplyx Raises $67m For Antifungals Against Life-Threatening Pathogens
Investors were impressed by the company's broad-spectrum, IV and oral antifungal drug in a space where few treatment options exist; Phase II trials will start later this year.
Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake
Exclusive contracts for J&J's Remicade have posed challenges for Pfizer's Inflectra in the commercial insurance market, the biosimilar's maker said during its second quarter earnings call.